Arterra Bioscience Spa · MIL:ARBS
Arterra Bioscience Spa — Investor Conference 2026 Banca Profilo
26 slides from Arterra Bioscience Spa's conference presentation, Apr 8, 2026
Slide 1: Investor Conference 2026 Banca Profilo
INVESTOR CONFERENCE 2026 Banca Profilo April 8 th , 2026
Slide 2: Index
INDEX TOPICS • ARTERRA AT GLANCE • MARKET CONSOLIDATION • FINANCIALS
Slide 3: People Speaking Today
PEOPLE SPEAKING TODAY MARIDA BIMONTE GUALTIERO IOIMO Project & IP Manager CFO and Investor Relations Manager
Slide 4: Arterra Bioscience - Innovative SME
ARTERRA BIOSCIENCE - Innovative SME Arterra Bioscience is a biotech company listed on the “Euronext Growth Milan” market of Borsa Italiana since 2019, founded in Naples by M. Gabriella Colucci in 2004 with the aim of developing technologies and innovative solutions that find application in various i
Slide 5: Arterra & Vitalab Team
ARTERRA & VITALAB TEAM 36 13 PhD 17 Chem Ing 2 MSc 11 Tech 11 Administration 6 1,600 sqm PhD Students 2
Slide 6: Our Facilities
OUR FACILITIES ❖ Chemistry Lab ❖ Plant Cell Culture Lab ❖ Microbiology Lab ❖ New ❖ Molecular & Cell Biol . Lab ❖ Histology & Microscopy Lab ❖ Process Lab ❖ Production Lab ❖ Plant Cells Culture Growing Facility ❖ MicroAlgae Growing Facility ❖ Lactobacillus & Agrobacterium Growing Facility ❖ Plant Gro
Slide 7: Management Team
MANAGEMENT TEAM M. GABRIELLA COLUCCI VINCENZO FOGLIANO ANNALISA TITO CEO CSO GIUSEPPE FERRANTE Cell & Mol Biol . Director COO GUALTIERO IOIMO MARIDA BIMONTE CFO Grant & IP Director
Slide 8: Company Organization
COMPANY ORGANIZATION President & CEO Gabriella Colucci Quality Management Assistant Assurance Accounting Financial Investor Relations Gualtiero Ioimo Alexandra Fellermeier Chief Operating Officer R&D Coordinator Giuseppe Ferrante Vincenzo Fogliano Cell Biology Director Cell Culture Vitalab : Annalis
Slide 9: From the Idea to the Product
FROM THE IDEA TO THE PRODUCT Microbiology Chemistry Scientific Breakthrough Biochemistry Genetic Engineering Plants New Tech . Skin Biology THINK TANK TEAM TTU Insight and Feasibility of Ideas THINK TANK RESEARCH UNITS Management Team Approval INNOVATION TEAM IU INNOVATION RESEARCH UNITS From Idea t
Slide 10: Arterra Position in Relevant Markets
ARTERRA POSITION IN RELEVANT MARKETS CONSUMER COSMETICS BEAUTY COSMETICS Skin Care, Make -Up, Personal Care & Hair Care Professional Cosmetic Products for topical consolidated market through Intercos & Vitalab . applications in Aestetic Medicine. New segment of a known market. Ingredients for topica
Slide 11: Sources for Active Ingredient Discovery & Development
SOURCES FOR ACTIVE INGREDIENT DISCOVERY & DEVELOPMENT BIOENGINEERING BASED 4 New Proprietary Strains of Lactobacillus BIOTECH BASED HIGH QUALITY EXTRACTS Plant Cell Culture MicroAlgae Wild Grown Plants Coltivated Mashroom (TCM) PATENT ON GENETIC ELEMENTS for Up Cycling Agricultural Waste Recombinant
Slide 12: Extraction Procedure
EXTRACTION PROCEDURE HYDROXYPROLINE RICH MULTIPEPTIDES Patent : WO 2007/104489 Gabriella Colucci, Fabio Apone, NEWLY INTRODUCED TRADITIONAL Maarten J. Chrispeels Method for the preparation of a composition based on 4 -hydroxyproline IN HOUSE TECHNOLOGY J. Biotechnol ., 145(4): 367-376 (2010). A mixt
Slide 13: Efficacy Evaluation Platform
EFFICACY EVALUATION PLATFORM Cosmetic and biomedical application IN-VITRO BIOLOGY EX -VIVO MODELS 21 Cell Lines Skin Explants & Hair Follicle 180 Assays 49 Assays PENETRATION PLATFORMS IN-VITRO GUT MODELS Skin artificial membrane In Vitro intestinal Models 5 Disease Models
Slide 14: Global Cosmetics Industry: Trends & Strategic Implications
Global Cosmetics Industry: Trends & Strategic Implications Market Key Market Arterra Overview Trends Dynamics Positioning • 2025 market size: ~$120bn • Hybrid Make -up • China: evolving regulatory • Biotech expertise • ~4% CAGR • Indie brands rise landscape • Fast time -to-market • Largest segment:
Slide 15: Innovation in Cosmetic
INNOVATION IN COSMETIC 2024/2026 - 8 NEW catalogue products on the market Vita PeptiBloom Vita NiaCeraMine PlantExo Vita Exorelis Vita Peonia suffructicosa Hyssopus Officinalis Exosome -based active ingredient Next-gen Exosomes plant cell cultures plant cell cultures from Plantago lanceolata plant c
Slide 16: Innovation in Cosmetic
INNOVATION IN COSMETIC 2025 EXCLUSIVE DEVELOPMENT FOR: n. 3 Exclusive Active Ingredients n. 1 Exclusive Active Ingredients n. 1 Exclusive Active Ingredients
Slide 17: Innovation in Cosmetic
INNOVATION IN COSMETIC CONSOLIDATED SEGMENT: SKINCARE & MAKE -UP & HAIRCARE 2024/2026 2024 2025 1. Tito A. et al. HPC Today, 1/2024. 1. Vitale A., et al. Critical Reviews in Biotechnology, 1 –18 (2025). 2. Di Lorenzo R., et al. International Journal of Molecular Sciences, 2024, 25, 2. Russo R., et a
Slide 18: Innovation in Cosmetic
INNOVATION IN COSMETIC 2024/2026 Patents filed 2024/2026 Patent granted • Domanda di brevetto internazionale PCT/EP 2024 /074175: Use of • Brevetto italiano n.102023000017877: Uso di estratti di origine plant -derived extracts for hair growth stimulation and cosmetic or vegetale per la stimolazione
Slide 19: Innovation in Medical Device
INNOVATION IN MEDICAL DEVICE 2021 - 1 NEW product launched on the market : Arterra BioComplex for acne treatment Products Partnership Technology Indication ADL Farmaceutici • Biotech -derived actives • Acne -prone skin • CE medical device Strategic value: expansion into medical devices & dermatologi
Slide 20: Innovation in Food Supplements and Medical Device
INNOVATION IN FOOD SUPPLEMENTS and MEDICAL DEVICE 2025 - 1 NEW product ready for the market : A combined oral and topical treatment for Atopic Dermatitis In vivo test on animal model* Clinical Trial* In vitro model of “atopic skin” In vitro model of "gut inflammation " LPS stimulation Raw 264.7 cell
Slide 21: Certifications
CERTIFICATIONS EF/CI Azienda certificata () da ClimatePartner climate-id.com/RUPASF ecovadis Sustainability Rating SEP 2024 m ArterraBioscience
Slide 22: Financials
FINANCIALS
Slide 23: Economic Results as of December 31, 2025
32,15% ECONOMIC RESULTS AS OF DECEMBER 31, 2025 VALUE OF PRODUCTION ( €/000) EBITDA ( €/000) NET INCOME ( €/000) 2.500 36,3% 33,0% 6.115 25,4% 2.222 2.006 125 21,7% 1.337 5.266 32,5% 4.950 2.000 35 1.340 32,1% 1.076 1.712 231 1.058 1.591 1.500 1.416 1.000 4.649 4.173 3.304 500 2023 2024 2025 - 2023
Slide 24: No Debt / Equity
NO DEBT / EQUITY NET DEBT ( €/000) EQUITY ( €/000) 12.582 2023 2024 2025 10.467 10.751 11.423 Cash and Cash Equivalents (3.686) (3.343) (1.343) Current Financial Receivables - - - Financial assets other than 891fixed 1.823 assets Current Financial Debt 86 96 93 Current Net Debt (3.599) (3.247) (1.25
Slide 25: Revenue Comparison - 2025 vs 2024
REVENUE COMPARISON - 2025 vs 2024 2025 vs 2024 2025 - 2024 Total Value of Production: Reached €6.12m, delivering a solid +16.1% YoY growth (from 7.000,00 16% €5.27m in 2024). 6.000,00 6.115,00 Core Business : 5.266,00 Sales and services revenues rose to €4.65m (+11.4%), 11% 5.000,00 confirming stead
Slide 26: Thank You
INVESTOR CONFERENCE MILAN Banca Profilo THANK YOU
Arterra Bioscience — Investor Conference 2026 Banca Profilo on 6ix